Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

NCT00412620 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00412620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00412620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
Lead sponsor
Abbott
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2006
Completion date
October 31, 2007
Enrollment
156 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia